Browse Studies — Arctuva

Real World Outcomes of Blinatumomab Consolidation in Patients With B-cell Acute Lymphoblastic Leukemia

This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys…

B-Cell Acute Lymphoblastic Leukaemia

Estimated

~$10 – $750

Medical College of WisconsinNCT07117136

Phase 1

A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally a…

Acute Lymphoblastic LeukaemiaAcute Myeloid LeukaemiaHigher-risk Myelodysplastic Syndromes

Estimated

~$10 – $7,500

AstraZenecaNCT07155226

Blinatumomab's Outcome On Serologic Titers and Efficacy of Revaccination

The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment f…

B-Cell ALLB-Cell Acute Lymphoblastic LeukaemiaB-Cell Lymphoblastic Leukemia+5 more

Estimated

~$10 – $750

Arkansas Children's Hospital Research InstituteNCT07422337